Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2019

View Archived Issues

Crystal structures may provide crystal ball for anti-TB drugs

Trial results reported for ublituximab, umbralisib and ibrutinib combination in B-cell malignancies

Resistin promotes VEGF-A expression and angiogenesis in chondrosarcoma through inhibition of a miRNA

Sylentis presents results from phase III HELIX study of tivanisiran

Bayer and Kyoto University form new research alliance in pulmonology

Veru initiates phase Ib/II study of VERU-111 in advanced mCRPC

Vanderbilt University describes muscarinic acetylcholine M4 receptor antagonists

New 5-HT-2A antagonists idenified at Tonix Pharmaceuticals

Syros Pharmaceuticals describes TAM receptor tyrosine kinase inhibitors

Ohio State University, Brigham and Women's Hospital patent SLC1A2 activators

Innate Tumor Immunity presents NACHT, LRR and PYD domains-containing protein 3 agonists

New bromodomain-containing protein 4 inhibitors reported by Zhejiang Hisun Pharmaceutical

Metrion Biosciences and LifeArc to collaborate on ion channel drug discovery project

Phase I results for LMB-100 plus nab-paclitaxel in pancreatic adenocarcinoma

Invenra, Wisconsin Alumni Research Foundation enter neuroblastoma collaboration

VEE TC-83 vaccine demonstrates safety in phase II study

Nanobiotix presents clinical data for NBTXR-3 in patients with HCC and liver metastasis

Theravance Biopharma presents novel dual AT1 antagonist/NEP inhibitor, TD-0212

Lacosamide shows promise in patients with Nav1.7-related small fiber neuropathy

Ipafricept found safe in patients with stage IV pancreatic cancer

MeiraGTx and Janssen collaborate on gene therapies for inherited retinal diseases

New pilot study of donor CMV-specific CTLs to treat CMV infection in transplant patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...